$ABT

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Abbott Laboratories (NYSE:ABT), Aqua Metals (NASDAQ:AQMS)

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.06% to 46,299.96 while the NASDAQ climbed 0.52% to 22,639.61. The S&P 500 also rose, gaining, 0.33% to 6,666.08. Communication services shares jumped by ...

Original reporting
Benzinga · Avi Kapoor
Published Oct 15, 2025, 6:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 15, 2025, 6:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Abbott Laboratories (NYSE:ABT), Aqua Metals (NASDAQ:AQMS) — source image
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

While some stocks are affected by earnings results, the overall market sentiment remains cautiously optimistic, with indices showing gains.

02

Market read

The news primarily impacts healthcare and manufacturing sectors, with moderate influence on broader market indices.

03

What to watch

Broader economic indicators and upcoming earnings reports could influence stock movements beyond current news.

Timing: short to medium term

Background

The recent earnings reports from Abbott Laboratories and Aqua Metals have led to short-term declines in their stock prices, amid a generally positive market environment.

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott Laboratories Q3 earnings report and stock performance.

Expected impact

Potential short-term decline of 2-3%, with recovery expected over the medium term.

Evidence & confidence

The immediate market reaction was negative, but fundamentals remain strong. Technical indicators suggest a possible rebound after initial sell-off.

$AQMSBearishMedium confidence
Context

Aqua Metals' stock decline post-earnings report.

Expected impact

Likely further decline of 3-5% if negative earnings trend persists.

Evidence & confidence

Earnings miss or guidance downgrade could exacerbate downward movement; technical support levels should be monitored.

Market effects

The news may influence the healthcare and manufacturing sectors, especially regarding earnings outlooks.

Limited regional impact; primarily U.S.-focused companies.

Moderate, as some companies have international operations, but overall impact remains localized.

Counterpoint

The market's negative reaction to earnings may be overdone, presenting buying opportunities for long-term investors.

Key entities

  • Abbott Laboratories

    A global healthcare company specializing in diagnostics, medical devices, and pharmaceuticals.

  • Aqua Metals

    A company focused on recycling and environmental solutions, particularly in battery recycling.

Related articles

$ABTMedAI 8/10

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten

Abbott (NYSE:ABT) received FDA authorization for Libre Duo, the first wearable to monitor glucose and ketones. The company plans a U.S. launch in 2026, targeting 8 million users. Abbott's stock is down 11% year-to-date, while competitor Dexcom (NASDAQ:DXCM) is up 34%. Abbott trades at a forward P/E of 21x with a $120.20 analyst target. Reimbursement expansion could drive growth, according to CEO Robert Ford.

$ABTMedAI 8/10

Abbott’s next-generation Amulet LAA occlusion device earns CE Mark

Abbott (NYSE: ABT) announced its Amulet 360 left atrial appendage occlusion device received CE Mark. The device, designed to reduce stroke risk in AFib patients, features dual-seal technology and improved conformability. A 400-patient study showed 99.8% successful implantation and 94% complete LAA closure. The device is now available in Europe and under investigation in the US.

$ABTMedAI 8/10

Abbott Receives CE Mark for Dissolving Stent

Abbott received CE Mark approval in Europe for its Esprit BTK System, a dissolvable stent for peripheral artery disease (PAD) below the knee. The system, which delivers everolimus, is designed to open arteries and dissolve over time. Clinical data showed a 48% reduction in repeat procedures compared to balloon angioplasty. Abbott aims to improve treatment options for PAD, a condition affecting 50 million Europeans.

$ABTHighAI 9/10

FDA authorises Abbott’s Libre Duo dual glucose-ketone sensor

Abbott (ABT) received FDA authorization for its Libre Duo 10 Day, a dual glucose-ketone sensor. The device is the first of its kind and is designed for people aged two and older. Abbott shares closed at $115.82 on 26 August, up 10.86% over 20 trading days. The company plans to launch the product in the US later in 2026, with compatibility for insulin pump systems from Beta Bionics and Sequel Med Tech. Medtronic's MiniMed unit (MMED) is also developing similar technology. Abbott reported $11.16bn

$ABTMed

Abbott secures CE mark for longer

Abbott received CE-mark approval for its 76mm Esprit BTK system to treat chronic limb-threatening ischaemia (CLTI). The longer-length device addresses the need to treat extensive below-the-knee lesions with fewer scaffolds, reducing procedural complexity. Abbott claims it is the only dissolving resorbable scaffold with robust long-term clinical evidence. The company sees this as an advancement for physicians in Europe, offering a solution for complex CLTI cases.